A number of important discoveries, therapeutic developments, and events related to pulmonary fibrosis (PF) were reported daily by Pulmonary Fibrosis News throughout 2016. Now that the year is over, it is time to briefly review the articles that appealed most to our readers. Here are the 10 most-read articles of 2016,…
News
So what is grief? Isn’t it just lots of crying? That is such a normal question. Grief is the process of letting go of someone or something that was deeply important to you. Grief is very different for each person, and comes in waves…
A University of Vermont medical professor has won a $6.3 million award to study antioxidant therapy as a possible treatment option for those with lung diseases such as pulmonary fibrosis (PF) and asthma. The National Heart, Lung, and Blood Institute (NHLBI) gave its first Outstanding…
A single microRNA was found to play a key role in lung fibrosis by regulating several signaling pathways involved in the release of pro-fibrotic signals. The study, “miR-323a-3p regulates lung fibrosis by targeting multiple profibrotic pathways,” was published in the journal JCI Insight. MicroRNAs are small…
The Viscira production company has won an international award for a 3D animated video about idiopathic pulmonary fibrosis (IPF) that it did in collaboration with Roche. The Academy of Interactive and Visual Arts gave its Silver Davey Award to Viscira for the best video in its category. The Davey…
Fat-free mass index (FFMI), a measure similar to body mass index (BMI) but that also takes into account the amount of muscle mass in the body is a significant predictor of survival in idiopathic pulmonary fibrosis (IPF) patients.
Wide access to potential molecular drug targets to treat pulmonary fibrosis is now possible, as researchers have mapped the complete set of genes active in individual lung cells from patients with idiopathic lung fibrosis and from healthy people. The analysis, called single-cell RNA sequencing, also made it possible to single out several…
Jordan Howard, the lead rusher for the Chicago Bears, is now auctioning his game-day Dec. 4 cleats in the NFL’s inaugural My Cause, My Cleats campaign to support the Pulmonary Fibrosis Foundation (PFF) and the pulmonary fibrosis (PF) community. The auction is open until Dec. 18, and the public can bid on…
Although previously limited to the pulmonary system, new research suggests that acute exacerbations in idiopathic pulmonary fibrosis (IPF) also involve multiple organ systems. Moreover, two genes, scavenger receptor A (SRA) and TNF-α, are thought to play a role in mediating this systemic tissue damage. Acute exacerbations is the all-encompassing term…
Promedior, a biotechnology company that focuses on anti-tissue-scarring therapies, has lined up the patients it needs for two Phase 2 studies of PRM-151, an anti-scarring agent it is evaluating for the treatment of idiopathic pulmonary fibrosis (IPF) and myelofibrosis. “We believe attaining these (patient) enrollment milestones speaks to both the…
